State Board of Administration of Florida Retirement System Reduces Stake in Eli Lilly And Co (LLY)

State Board of Administration of Florida Retirement System decreased its holdings in Eli Lilly And Co (NYSE:LLY) by 0.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,338,457 shares of the company’s stock after selling 11,329 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Eli Lilly And Co were worth $114,211,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of LLY. BlackRock Inc. grew its stake in shares of Eli Lilly And Co by 3.0% in the 1st quarter. BlackRock Inc. now owns 65,780,446 shares of the company’s stock valued at $5,089,436,000 after buying an additional 1,926,334 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of Eli Lilly And Co by 14.1% in the 1st quarter. Franklin Resources Inc. now owns 32,541,775 shares of the company’s stock valued at $2,517,762,000 after buying an additional 4,022,251 shares in the last quarter. Schroder Investment Management Group grew its stake in shares of Eli Lilly And Co by 103.8% in the 1st quarter. Schroder Investment Management Group now owns 4,689,223 shares of the company’s stock valued at $362,806,000 after buying an additional 2,388,548 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in shares of Eli Lilly And Co by 2.0% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 4,335,040 shares of the company’s stock valued at $335,403,000 after buying an additional 85,455 shares in the last quarter. Finally, Fisher Asset Management LLC grew its stake in shares of Eli Lilly And Co by 5.1% in the 2nd quarter. Fisher Asset Management LLC now owns 3,710,066 shares of the company’s stock valued at $316,580,000 after buying an additional 180,855 shares in the last quarter. Institutional investors own 76.62% of the company’s stock.

LLY has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating on shares of Eli Lilly And Co in a research note on Wednesday, April 18th. Credit Suisse Group set a $80.00 price target on Eli Lilly And Co and gave the company a “hold” rating in a research note on Sunday, April 22nd. BMO Capital Markets reissued a “hold” rating and issued a $79.00 price target on shares of Eli Lilly And Co in a research note on Tuesday, April 24th. ValuEngine cut Eli Lilly And Co from a “hold” rating to a “sell” rating in a research note on Wednesday, May 2nd. Finally, Barclays set a $98.00 price target on Eli Lilly And Co and gave the company a “buy” rating in a research note on Tuesday, May 22nd. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $100.13.

Shares of Eli Lilly And Co opened at $102.25 on Friday, Marketbeat.com reports. The company has a market cap of $109.75 billion, a price-to-earnings ratio of 23.89, a P/E/G ratio of 1.70 and a beta of 0.27. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.40 and a quick ratio of 1.09. Eli Lilly And Co has a 12-month low of $73.69 and a 12-month high of $103.81.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Tuesday, July 24th. The company reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.20. The firm had revenue of $6.36 billion during the quarter, compared to analysts’ expectations of $6.05 billion. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. The company’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.11 earnings per share. equities analysts predict that Eli Lilly And Co will post 5.47 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, September 10th. Shareholders of record on Wednesday, August 15th will be given a dividend of $0.5625 per share. The ex-dividend date is Tuesday, August 14th. This represents a $2.25 dividend on an annualized basis and a yield of 2.20%. Eli Lilly And Co’s payout ratio is currently 52.57%.

In other Eli Lilly And Co news, SVP Christi Shaw sold 8,426 shares of the company’s stock in a transaction that occurred on Tuesday, May 29th. The stock was sold at an average price of $82.10, for a total transaction of $691,774.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 195,000 shares of the company’s stock in a transaction that occurred on Monday, August 6th. The stock was sold at an average price of $102.15, for a total value of $19,919,250.00. Following the sale, the insider now directly owns 120,735,804 shares of the company’s stock, valued at approximately $12,333,162,378.60. The disclosure for this sale can be found here. Insiders have sold 1,575,728 shares of company stock valued at $144,624,164 in the last ninety days. Company insiders own 0.11% of the company’s stock.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: Leveraged Buyout (LBO) Explained

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit